IN2012CH01573A - - Google Patents
Download PDFInfo
- Publication number
- IN2012CH01573A IN2012CH01573A IN1573CH2012A IN2012CH01573A IN 2012CH01573 A IN2012CH01573 A IN 2012CH01573A IN 1573CH2012 A IN1573CH2012 A IN 1573CH2012A IN 2012CH01573 A IN2012CH01573 A IN 2012CH01573A
- Authority
- IN
- India
- Prior art keywords
- compounds
- bruton
- btk
- formula
- tyrosine kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201380019452.8A CN104662018B (zh) | 2012-04-20 | 2013-04-18 | 取代的杂双环化合物、组合物及其医疗应用 |
IN1573CH2012 IN2012CH01573A (zh) | 2012-04-20 | 2013-04-18 | |
CA2869954A CA2869954C (en) | 2012-04-20 | 2013-04-18 | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof in medical conditions related to modulation of bruton's tyrosine kinase activity |
JP2015506355A JP6182593B2 (ja) | 2012-04-20 | 2013-04-18 | 置換ヘテロ二環化合物、組成物及び医薬並びにそれらの用途 |
AU2013250726A AU2013250726B2 (en) | 2012-04-20 | 2013-04-18 | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
PCT/IN2013/000259 WO2013157022A1 (en) | 2012-04-20 | 2013-04-18 | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
EP13737672.9A EP2838898B1 (en) | 2012-04-20 | 2013-04-18 | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
US14/509,793 US9233983B2 (en) | 2012-04-20 | 2014-10-08 | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
ZA2014/07341A ZA201407341B (en) | 2012-04-20 | 2014-10-09 | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
IL235146A IL235146A (en) | 2012-04-20 | 2014-10-19 | Converted heterocyclic compounds, preparations and their medical applications |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1573CH2012 IN2012CH01573A (zh) | 2012-04-20 | 2013-04-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012CH01573A true IN2012CH01573A (zh) | 2015-07-10 |
Family
ID=48794150
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN1573CH2012 IN2012CH01573A (zh) | 2012-04-20 | 2013-04-18 |
Country Status (10)
Country | Link |
---|---|
US (1) | US9233983B2 (zh) |
EP (1) | EP2838898B1 (zh) |
JP (1) | JP6182593B2 (zh) |
CN (1) | CN104662018B (zh) |
AU (1) | AU2013250726B2 (zh) |
CA (1) | CA2869954C (zh) |
IL (1) | IL235146A (zh) |
IN (1) | IN2012CH01573A (zh) |
WO (1) | WO2013157022A1 (zh) |
ZA (1) | ZA201407341B (zh) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2571361A4 (en) | 2010-05-19 | 2013-11-13 | Univ North Carolina | PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT |
AU2012318896B2 (en) | 2011-10-03 | 2017-03-02 | The University Of North Carolina At Chapel Hill | Pyrrolopyrimidine compounds for the treatment of cancer |
EP2852579A4 (en) | 2012-05-22 | 2015-12-30 | Univ North Carolina | PYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER |
AP2015008203A0 (en) | 2012-08-10 | 2015-01-31 | Boehringer Ingelheim Int | Heteroaromatic compounds as bruton's tyrosine kinase (BTK) inhibitors |
WO2014062774A1 (en) | 2012-10-17 | 2014-04-24 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
US9771330B2 (en) | 2012-11-27 | 2017-09-26 | The University Of North Carolina At Chapel Hill | Pyrimidine compounds for the treatment of cancer |
CA2905530A1 (en) * | 2013-03-14 | 2014-09-18 | Abbvie Inc. | Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors |
CN104211703B (zh) * | 2013-05-30 | 2018-04-03 | 南京勇山生物科技有限公司 | 一类作为布鲁顿激酶抑制剂的稠杂环化合物 |
US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
WO2015157122A1 (en) | 2014-04-11 | 2015-10-15 | The University Of North Carolina At Chapel Hill | Mertk-specific pyrazolopyrimidine compounds |
CN105294571B (zh) | 2014-07-03 | 2019-04-23 | 浙江九洲药业股份有限公司 | 一种依鲁替尼中间体及其制备方法和用途 |
NZ729137A (en) | 2014-08-04 | 2022-07-29 | Nuevolution As | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases |
US10253023B2 (en) * | 2014-10-06 | 2019-04-09 | Merck Patent Gmbh | Heteroaryl compounds as BTK inhibitors and uses thereof |
US10272070B2 (en) | 2014-10-14 | 2019-04-30 | The Board of Trustees of the Leland Stanford Junio r University | Method for treating neurodegenerative diseases |
HUE050706T2 (hu) | 2014-10-24 | 2020-12-28 | Bristol Myers Squibb Co | Indol karboxamid vegyületek, amelyek hasznosak kináz inhibitorokként |
EP3042903B1 (en) * | 2015-01-06 | 2019-08-14 | Impetis Biosciences Ltd. | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
MX2017016370A (es) | 2015-06-18 | 2018-04-11 | Cephalon Inc | Derivados de 4-bencil y 4-benzoil piperidina sustituidos. |
CN107847765B (zh) | 2015-06-18 | 2021-05-04 | 89生物有限公司 | 1,4-取代的哌啶衍生物 |
GB201517217D0 (en) * | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
GB201517216D0 (en) * | 2015-09-29 | 2015-11-11 | Cancer Res Technology Ltd And Astex Therapeutics Ltd | Pharmaceutical compounds |
EP3390367B1 (en) | 2015-12-15 | 2020-09-09 | The Board of Trustees of the Leland Stanford Junior University | Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation |
EP3402789B1 (en) * | 2016-01-13 | 2020-03-18 | Boehringer Ingelheim International Gmbh | Isoquinolones as btk inhibitors |
US10709708B2 (en) | 2016-03-17 | 2020-07-14 | The University Of North Carolina At Chapel Hill | Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor |
WO2017181117A1 (en) | 2016-04-15 | 2017-10-19 | Blueprint Medicines Corporation | Inhibitors of activin receptor-like kinase |
CA2969295A1 (en) | 2016-06-06 | 2017-12-06 | Pfizer Inc. | Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor |
CN109641892B (zh) * | 2016-08-16 | 2021-07-02 | 默克专利有限公司 | 用作可逆btk抑制剂的2-氧代-咪唑并吡啶及其用途 |
US10793575B2 (en) | 2016-11-25 | 2020-10-06 | Carna Biosciences, Inc. | Oxoisoquinoline derivatives |
CN106883235B (zh) * | 2016-12-29 | 2019-04-30 | 天津国际生物医药联合研究院 | 恶二唑类化合物的制备和应用 |
CN110072865B (zh) * | 2017-02-08 | 2022-02-11 | 中国医药研究开发中心有限公司 | 吡咯并芳杂环类化合物及其制备方法和医药用途 |
CN108794480A (zh) * | 2017-04-28 | 2018-11-13 | 天津药物研究院有限公司 | 吡咯并嘧啶类化合物、其制备方法和用途 |
EP3697786B1 (en) | 2017-10-18 | 2022-08-31 | Blueprint Medicines Corporation | Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase |
WO2019116302A1 (en) * | 2017-12-13 | 2019-06-20 | Lupin Limited | Substituted bicyclic heterocyclic compounds as prmt5 inhibitors |
CN109293638B (zh) * | 2018-03-27 | 2020-08-14 | 大连理工大学 | 一种增强型的靶向识别受体酪氨酸激酶的荧光传感器及细胞膜荧光成像的应用 |
CN108707154A (zh) * | 2018-07-10 | 2018-10-26 | 刘凤娟 | 一种治疗癌症的药物溶剂合物及其制备方法 |
JP7422737B2 (ja) | 2018-08-06 | 2024-01-26 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 神経変性疾患を治療するためのPpargc1a活性化剤としての2‐アリールベンゾイミダゾール |
US11548884B2 (en) * | 2018-09-06 | 2023-01-10 | Hoffmann-La Roche Inc. | Cyclic amidine compounds for the treatment of autoimmune disease |
CN109369619A (zh) * | 2018-10-04 | 2019-02-22 | 南京先进生物材料与过程装备研究院有限公司 | 酞嗪酮类化合物晶型b及其制备方法 |
CN109336864A (zh) * | 2018-10-04 | 2019-02-15 | 南京先进生物材料与过程装备研究院有限公司 | 酞嗪酮类化合物晶型n及其制备方法 |
CN109180644A (zh) * | 2018-10-04 | 2019-01-11 | 南京先进生物材料与过程装备研究院有限公司 | 一种新型btk激酶抑制剂的甲磺酸盐及其制备方法与用途 |
CN109336863A (zh) * | 2018-10-04 | 2019-02-15 | 南京先进生物材料与过程装备研究院有限公司 | 一种新型酞嗪酮类btk抑制剂、制备及其应用 |
CN109485636A (zh) * | 2018-10-04 | 2019-03-19 | 南京先进生物材料与过程装备研究院有限公司 | 一种新型btk激酶抑制剂的盐酸盐及其制备方法与用途 |
CN109180643A (zh) * | 2018-10-04 | 2019-01-11 | 南京先进生物材料与过程装备研究院有限公司 | 酞嗪酮类化合物晶型a及其制备方法 |
CN109180642A (zh) * | 2018-10-04 | 2019-01-11 | 南京先进生物材料与过程装备研究院有限公司 | 酞嗪酮类btk抑制剂及其应用 |
CN109293635A (zh) * | 2018-10-04 | 2019-02-01 | 南京先进生物材料与过程装备研究院有限公司 | 一种新型btk激酶抑制剂的p晶型及其制备方法 |
HRP20231673T1 (hr) * | 2019-06-10 | 2024-03-15 | Lupin Limited | Inhibitori prmt5 |
CN110305140B (zh) * | 2019-07-30 | 2020-08-04 | 上海勋和医药科技有限公司 | 二氢吡咯并嘧啶类选择性jak2抑制剂 |
WO2021120890A1 (en) * | 2019-12-20 | 2021-06-24 | Novartis Ag | Pyrazolyl derivatives useful as anti-cancer agents |
WO2021124277A1 (en) | 2019-12-20 | 2021-06-24 | Nuevolution A/S | Compounds active towards nuclear receptors |
AU2021249530A1 (en) | 2020-03-31 | 2022-12-01 | Nuevolution A/S | Compounds active towards nuclear receptors |
MX2022012260A (es) | 2020-03-31 | 2022-11-30 | Nuevolution As | Compuestos activos frente a receptores nucleares. |
WO2022140246A1 (en) | 2020-12-21 | 2022-06-30 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0115109D0 (en) | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
GB0115393D0 (en) | 2001-06-23 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
JP2005502643A (ja) * | 2001-08-10 | 2005-01-27 | ノバルティス アクチエンゲゼルシャフト | 白血病処置のための単独またはsti571と組み合せたc−srcインヒビターの使用 |
AU2002352663B2 (en) | 2001-11-13 | 2007-06-21 | Axys Pharmaceuticals, Inc. | Cyanoalkylamino derivatives as protease inhibitors |
US20060183746A1 (en) * | 2003-06-04 | 2006-08-17 | Currie Kevin S | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
CN101124227A (zh) * | 2004-11-10 | 2008-02-13 | Cgi制药有限公司 | 可用作激酶活性调节剂的咪唑并[1,2-a]吡嗪-8-基胺 |
ES2337831T3 (es) | 2005-06-24 | 2010-04-29 | Bristol-Myers Squibb Company | Derivados de fenilglicinamida y piridilclicinamida utiles como agentes anticoagulantes. |
JP5321061B2 (ja) * | 2005-08-11 | 2013-10-23 | アリアド・ファーマシューティカルズ・インコーポレイテッド | 不飽和複素環誘導体 |
US7786130B2 (en) | 2005-08-29 | 2010-08-31 | Vertex Pharmaceuticals Incorporated | Pyridones useful as inhibitors of kinases |
WO2007067537A1 (en) | 2005-12-07 | 2007-06-14 | Osi Pharmaceuticals, Inc. | Pyrrolopyridine kinase inhibiting compounds |
AR064491A1 (es) | 2006-12-22 | 2009-04-08 | Astex Therapeutics Ltd | Derivados de imidazo[1, 2-a]pirimidina, un proceso para su preparacion, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por las quinasas fgfr. |
US7989465B2 (en) | 2007-10-19 | 2011-08-02 | Avila Therapeutics, Inc. | 4,6-disubstituted pyrimidines useful as kinase inhibitors |
RU2505538C2 (ru) | 2008-02-05 | 2014-01-27 | Ф.Хоффманн-Ля Рош Аг | Новые пиридиноны и пиридазиноны |
CA2718403A1 (en) | 2008-03-13 | 2009-09-17 | The General Hospital Corporation | Inhibitors of the bmp signaling pathway |
CN102119163A (zh) | 2008-06-11 | 2011-07-06 | 健泰科生物技术公司 | 二氮杂咔唑和使用方法 |
WO2010000633A1 (en) | 2008-07-02 | 2010-01-07 | F. Hoffmann-La Roche Ag | Novel phenylpyrazinones as kinase inhibitors |
JP2011526931A (ja) | 2008-07-03 | 2011-10-20 | エグゼリクシス, インコーポレイテッド | Cdkモジュレーター |
WO2010005783A1 (en) | 2008-07-08 | 2010-01-14 | Boehringer Ingelheim International Gmbh | Pyrrolidinyl and piperidinyl compounds useful as nhe-1 inhibitors |
UY31984A (es) | 2008-07-16 | 2010-02-26 | Boehringer Ingelheim Int | DERIVADOS DE 1-(3,4-difluorobencil)-6-oxo-1,6-dihidropirimidin-5-carboxamidas N-sustituidas y de 2-(3,4-difluorobencil)-3-oxo-2,3-dihidro-1H-pirazol-4-carboxamidas N-sustituidas. |
ES2461494T3 (es) | 2008-07-18 | 2014-05-20 | F. Hoffmann-La Roche Ag | Nuevas fenilimidazopirazinas |
WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
WO2010068788A1 (en) | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Heterocyclic amides as btk inhibitors |
WO2010068810A2 (en) | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
WO2010068806A1 (en) * | 2008-12-10 | 2010-06-17 | Cgi Pharmaceuticals, Inc. | Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer |
WO2010080481A1 (en) | 2008-12-19 | 2010-07-15 | Bristol-Myers Squibb Company | Carbazole carboxamide compounds useful as kinase inhibitors |
US8299077B2 (en) | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
ES2513915T3 (es) | 2009-04-24 | 2014-10-27 | F. Hoffmann-La Roche Ag | Inhibidores de la tirosina quinasa de Bruton |
JP2012529535A (ja) | 2009-06-12 | 2012-11-22 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼモジュレーターとして有用なニコチンアミド化合物 |
US8846673B2 (en) | 2009-08-11 | 2014-09-30 | Bristol-Myers Squibb Company | Azaindazoles as kinase inhibitors and use thereof |
WO2011029046A1 (en) * | 2009-09-04 | 2011-03-10 | Biogen Idec Ma Inc. | Bruton's tyrosine kinase inhibitors |
US7741330B1 (en) | 2009-10-12 | 2010-06-22 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase |
UA110025C2 (xx) | 2010-01-27 | 2015-11-10 | Піразоли як антагоністи crth2 | |
US9307625B2 (en) * | 2011-04-05 | 2016-04-05 | Eth Zurich | Droplet dispensing device and light source comprising such a droplet dispensing device |
CA2841111A1 (en) * | 2011-07-08 | 2013-01-17 | Novartis Ag | Novel pyrrolo pyrimidine derivatives |
BR112014003582A2 (pt) | 2011-08-17 | 2017-03-14 | Hoffmann La Roche | inibidores da tirosina quinase de bruton |
-
2013
- 2013-04-18 IN IN1573CH2012 patent/IN2012CH01573A/en unknown
- 2013-04-18 CN CN201380019452.8A patent/CN104662018B/zh not_active Expired - Fee Related
- 2013-04-18 AU AU2013250726A patent/AU2013250726B2/en not_active Ceased
- 2013-04-18 CA CA2869954A patent/CA2869954C/en active Active
- 2013-04-18 JP JP2015506355A patent/JP6182593B2/ja active Active
- 2013-04-18 EP EP13737672.9A patent/EP2838898B1/en active Active
- 2013-04-18 WO PCT/IN2013/000259 patent/WO2013157022A1/en active Application Filing
-
2014
- 2014-10-08 US US14/509,793 patent/US9233983B2/en active Active
- 2014-10-09 ZA ZA2014/07341A patent/ZA201407341B/en unknown
- 2014-10-19 IL IL235146A patent/IL235146A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CN104662018B (zh) | 2017-10-24 |
CA2869954C (en) | 2023-01-03 |
CN104662018A (zh) | 2015-05-27 |
WO2013157022A1 (en) | 2013-10-24 |
CA2869954A1 (en) | 2013-10-24 |
JP2015514749A (ja) | 2015-05-21 |
EP2838898A1 (en) | 2015-02-25 |
ZA201407341B (en) | 2015-06-24 |
JP6182593B2 (ja) | 2017-08-16 |
AU2013250726B2 (en) | 2017-01-05 |
IL235146A (en) | 2017-07-31 |
US20150064196A1 (en) | 2015-03-05 |
EP2838898B1 (en) | 2017-01-18 |
AU2013250726A1 (en) | 2014-10-09 |
US9233983B2 (en) | 2016-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012CH01573A (zh) | ||
MX354412B (es) | Composiciones y metodos para la produccion de compuestos de pirimidina con actividad inhibidora de tirosina cinasa de bruton. | |
PH12018502125A1 (en) | Bipyrazole derivatives as jak inhibitors | |
IN2015DN02008A (zh) | ||
PH12018500533A1 (en) | Pyrazolyl-substituted heteroaryls and their use as medicaments | |
PH12016501440A1 (en) | Novel heterocyclic compounds | |
EA201492250A1 (ru) | Гетероциклическое соединение | |
MX2015001715A (es) | Compuestos de pirrolopirimidina novedosos como inhibidores de proteinas quinasas. | |
MY155639A (en) | 2, 6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors | |
SG194728A1 (en) | Inhibitors of bruton's tyrosine kinase | |
MX2014014828A (es) | Compuestos de 5-azaindazol y metodos de uso. | |
NZ629432A (en) | Heterocyclyl compounds as mek inhibitors | |
MX2014005285A (es) | Compuestos biciclicos de piperazina. | |
MY143483A (en) | Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders | |
WO2014172513A3 (en) | 3,5-(un)substituted-1h-pyrrolo[2,3-b]pyridine, 1h-pyrazolo[3,4-b]pyridine and 5h-pyrrolo [2-,3-b]pyrazine dual itk and jak3 kinase inhibitors | |
MX349372B (es) | Inhibidores de la tirosina-cinasa de bruton. | |
EA201592033A1 (ru) | 3-(2-АМИНОПИРИМИДИН-4-ИЛ)-5-(3-ГИДРОКСИПРОПИНИЛ)-1H-ПИРРОЛО[2,3-c]ПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ NIK ДЛЯ ЛЕЧЕНИЯ РАКА | |
NZ601267A (en) | Fused heteroaromatic pyrrolidinones as syk inhibitors | |
MX2013012776A (es) | Inhibidores de la tirosina cinasa de bazo que contienen aminopiridina. | |
MX336051B (es) | Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa. | |
EP2635587A1 (en) | Novel 6-arylamino pyridone carboxamide as mek inhibitors | |
PH12016501977A1 (en) | 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES | |
WO2014093230A3 (en) | Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity | |
EA201700042A1 (ru) | Соединения имидазопиридазина | |
MX2015010983A (es) | Inhibidores de tirosina-cinasa de bruton. |